Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.

Journal Title: Pharmacological Reports - Year 2011, Vol 63, Issue 3

Abstract

The aim of this study was to retrospectively evaluate the effect of polymorphisms in the CYP3A4, CYP3A5 and ABCB1 genes on the dose-adjusted concentration and dose requirement of cyclosporine A(CsA) in Chinese recipients during the early period after bone marrow or hematopoietic stem cell transplantation. Ninety-one bone marrow transplant recipients were genotyped by the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay or by direct sequencing for the C1236T, G2677T/A and C3435T polymorphisms in CYP3A4*18B, CYP3A5*3, and ABCB1, respectively. The concentration at zero before administration (C(0)) and concentration at 2 h after administration (C(2)) of whole blood CsA were measured by fluorescence polarization immunoassay. Dose-adjusted C(0) and C(2) were determined and compared among groups with different genotypes. Compared with CYP3A5*3/*3 individuals, CYP3A5*1/*1 subjects have a significantly lower dose-adjusted C(0) and C(2) at days 1-10 and a higher dose requirement for CsA at days 16-30 (p < 0.05). In addition, homozygotes for the ABCB1 3435T mutant have a significantly higher dose-adjusted C(0) and C(2) and a lower dose requirement compared with wildtype (p < 0.05). Similar results were also derived for carriers of the T-G-C haplotype in CYP3A5 producers compared with non-carriers (p < 0.05 and p < 0.01, respectively). In summary, the ABCB1 3435T SNP, T-G-C haplotype in CYP3A5 producers, and CYP3A5*3 SNP are all associated with differences in CsA pharmacokinetics and dose requirements during the first month after bone marrow or hematopoietic stem cell transplantation. Genetic testing can therefore help to determine initial dosage and individualize immunosuppressive therapy.

Authors and Affiliations

Feng Qiu, Xiao-Jing He, Ya-Xin Sun, Jesse Li-Ling, Li-Mei Zhao

Keywords

Related Articles

Mechanisms of [Ca(2+)]i elevation following P2X receptor activation in the guinea-pig small mesenteric artery myocytes.

Background: There is growing evidence suggesting involvement of L-type voltage-gated Ca(2+) channels (VGCCs) in purinergic signaling mechanisms. However, detailed interplay between VGCCs and P2X receptors in intracellula...

Effects of sildenafil treatment on the development of tolerance to diazepam-induced motor impairment and sedation in mice.

We studied the effects of sildenafil, a selective inhibitor of PDE5, on the development and the expression of tolerance to diazepam (DZ)-induced motor impairment and sedation in mice. DZ-induced motor incoordination was...

Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients.

Background: Therapeutic effects of all clinically used antipsychotics are related to the reduction of dopaminergic transmission in the limbic system. The aim of present study was two-fold. First, efficacy of atypical dru...

σ Receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation.

Background: Methamphetamine (METH) causes hyperthermia and dopaminergic neurotoxicity in the rodent striatum. METH interacts with σ receptors and σ receptor antagonists normally mitigate METH-induced hyperthermia and dop...

Effects of diphenhydramine and famotidine on lipid peroxidation and activities of antioxidant enzymes in different rat tissues.

The potential antioxidant activity of diphenhydramine (histamine H(1)-receptor antagonist) and famotidine (histamine H(2) receptor antagonist) was studied. Diphenhydramine inhibited the spontaneous, Fe(II)-induced and Fe...

Download PDF file
  • EP ID EP139943
  • DOI -
  • Views 102
  • Downloads 0

How To Cite

Feng Qiu, Xiao-Jing He, Ya-Xin Sun, Jesse Li-Ling, Li-Mei Zhao (2011). Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.. Pharmacological Reports, 63(3), 815-825. https://europub.co.uk/articles/-A-139943